Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB)

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) will host the third annual Contemporary Landscapes in Muscle Biology (CLIMB) symposium on May 29, 2026, from 8:00 AM to 5:00 PM PT at the Mission Bay Conference Center in San Francisco.

Registration is free but capacity-limited, with an online deadline of May 22, 2026. CLIMB 2026 features a keynote by James A. Spudich, PhD, and expert sessions on cardiac biology, skeletal muscle biology and emerging treatment modalities, including genetic medicines, RNA medicines and muscle preservation.

News Market Reaction – CYTK

+1.84%

+1.84% Session close to close

In the May 14 session, CYTK gained 1.84%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Cytokinetics’ role in convening experts around muscle biology through t...

Analysis

This announcement highlights Cytokinetics’ role in convening experts around muscle biology through the CLIMB symposium on May 29, 2026. The event showcases topics spanning cardiac and skeletal muscle biology and emerging modalities like gene and RNA-based therapies. In recent months, the company has combined scientific progress with major financings and MYQORZO launch updates. Investors may focus on how such scientific visibility complements prior catalysts, including Phase 3 data, equity offerings, and the Nov 14, 2026 PDUFA date.

Key Figures

Symposium iteration: Third annual Event date: May 29, 2026 Event time: 8:00 AM to 5:00 PM Pacific Time +1 more

4 metrics

Symposium iteration Third annual Third annual CLIMB muscle biology research symposium

Event date May 29, 2026 Symposium scheduled date

Event time 8:00 AM to 5:00 PM Pacific Time Duration of one-day CLIMB symposium

Registration deadline May 22, 2026 Online registration cut-off for attendees

Historical Context

5 past events · Latest: May 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 11	Clinical data update	Positive	-3.1%	New MYQORZO Phase 3 and real-world data at ESC Heart Failure 2026.
May 08	Equity offering close	Negative	+3.5%	Closing of common stock offering with gross proceeds of about $805M.
May 06	Equity offering pricing	Negative	-0.7%	Pricing of upsized public offering at $71.00 per share for ~$700M.
May 05	Equity offering proposed	Negative	-2.9%	Announcement of proposed ~$650M underwritten common stock offering.
May 05	Earnings & update	Positive	-2.9%	Q1 2026 results, MYQORZO launch metrics, EU approval and PDUFA date.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often saw negative reactions even to seemingly positive clinical and earnings updates, while reactions to equity offerings have been mixed.

Recent Company History

Over the past weeks, Cytokinetics has reported multiple key developments. On May 5, 2026, Q1 results highlighted the U.S. launch of MYQORZO, $4.8M in early net product revenue, a positive ACACIA-HCM readout, EU approval for MYQORZO, and a FDA PDUFA date of Nov 14, 2026. This appeared positive but coincided with a -2.92% move. A series of common stock offerings between May 5–8, 2026 raised up to $805M, drawing mixed price reactions. On May 11, 2026, favorable Phase 3 and real-world MYQORZO data nonetheless saw the stock down 3.06% the next day.

Key Terms

myosin, cardiomyopathy, heart failure, pluripotent stem cell, +4 more

8 terms

myosin medical

"Keynote: Myosin: An Exquisite Nanomachine and the Power of Basic Research"

A protein that acts like tiny motors inside cells, converting chemical fuel into pull or push to make muscles contract and move things within cells. Investors care because drugs or tests that target myosin can change how well hearts beat, how muscles work, or treat certain diseases, so advances or setbacks in related research can affect the value of biotech and medical-device companies, much like a new engine design can shift an automaker’s prospects.

cardiomyopathy medical

"Energy Metabolism in Cardiomyopathy and Heart Failure"

A condition that weakens or stiffens the heart muscle, reducing its ability to pump blood effectively; think of the heart as an engine that becomes less powerful or less flexible. For investors, cardiomyopathy matters because it can drive demand for medical treatments, affect healthcare costs, influence the value of companies developing drugs or devices, and trigger regulatory or insurance impacts that change revenues and risks across the healthcare sector.

heart failure medical

"Energy Metabolism in Cardiomyopathy and Heart Failure"

A condition in which the heart cannot pump enough blood to meet the body's needs, causing fatigue, shortness of breath, fluid buildup, and reduced activity. It matters to investors because it drives demand for medicines, medical devices, hospital care, and long-term support services; outcomes, trial results, approvals, or changes in treatment guidelines can materially affect company revenues, healthcare costs, and market valuations. Think of it as a central pump losing efficiency and changing the economics of care.

pluripotent stem cell medical

"Regenerative Potential of Human Pluripotent Stem Cell Derived Skeletal Muscle"

A pluripotent stem cell is a basic biological building block that can be guided to develop into many different specialized cell types found in the body, like heart, nerve, or liver cells. For investors, these cells matter because they underpin a wide range of potential therapies and lab-made tissues with large market upside, but they also bring long development timelines, regulatory scrutiny, manufacturing challenges, and ethical and safety risks that affect value and timing of returns.

aav-crispr medical

"Modeling and Treating Disease by In Vivo Gene Editing with AAV-CRISPR"

AAV‑CRISPR is a gene‑editing approach that uses harmless viral particles (adeno‑associated virus, or AAV) as delivery trucks to carry CRISPR “molecular scissors” into specific cells and change DNA sequences. Investors care because it promises one‑time treatments that can permanently alter the course of genetic diseases—offering large potential rewards—but it also carries high scientific, regulatory and manufacturing risks that affect development timelines and commercial viability.

gene therapies medical

"Immune-Mediated Cardiac Injury: From Checkpoints to Gene Therapies"

Gene therapies are medical treatments that change or replace a person’s genetic instructions to fix or counteract a disease, using biological delivery methods to get the new material into cells — like repairing or swapping pages in a faulty instruction manual. They matter to investors because they can offer one-time or long-lasting cures with large market potential, but carry high development costs, regulatory scrutiny and manufacturing challenges that make outcomes binary and investment risky.

genetic medicines medical

"Emerging Genetic Medicines for Cardiomyopathies"

Genetic medicines are treatments that work by changing, replacing, or reprogramming a person’s genes or the instructions those genes send, with the goal of preventing or curing disease rather than just easing symptoms. For investors, they matter because they can offer transformative, often one-time therapies that command high prices and durable outcomes, but they also carry long development timelines, regulatory scrutiny and complex manufacturing risks — like backing a high-reward, high-risk technology startup.

rna medicines medical

"Unlocking the Broad Potential of RNA Medicines to Transform Human Health"

RNA medicines are treatments that use strands of genetic material called RNA to instruct cells to make, stop making, or alter specific proteins, similar to giving a factory a temporary set of blueprints to change what it produces. They matter to investors because this approach can enable faster development of targeted therapies and vaccines, create new revenue streams if successful, and carry distinct manufacturing and regulatory risks that can affect a company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Third Annual Muscle Biology-Focused Research Symposium 
Highlighting Recent Innovations in the Field

SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the third annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 29, 2026 from 8:00 AM to 5:00 PM Pacific Time. The event will be held at the Mission Bay Conference Center in San Francisco, CA.

Registration for the symposium is now open and available at no cost to attendees; however, capacity is limited. Interested parties must register online by May 22, 2026, at https://climbsymposium.com/.

“CLIMB has become an important forum for advancing dialogue and discovery in muscle biology,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “As the science continues to evolve, we are proud to convene researchers and innovators whose work is deepening our understanding of the underlying mechanisms of muscle function and uncovering new frontiers in the field.”

CLIMB is an annual one-day in-person research symposium bringing together scientists, researchers and emerging professionals to share innovative research in the field of muscle biology. The symposium seeks to foster collaboration, facilitate networking opportunities and promote interdisciplinary dialogue, with the ultimate goal of driving advancements in the biological understanding and emerging treatment of muscle-related diseases and disorders. CLIMB will feature distinguished expert speakers alongside poster presentations of novel research in the field of muscle biology. Presentations will focus on innovations in cardiac biology, skeletal muscle biology and emerging treatment modalities in muscle biology.

CLIMB 2026 will feature the following presentations:

Keynote:

• Myosin: An Exquisite Nanomachine and the Power of Basic Research in Drug Discovery
  James A. Spudich, PhD
  Co-Founder, Cytokinetics
  Stanford University, School of Medicine, Department of Biochemistry
  
  

Session 1: Cardiac Biology

• Chromatin Control of Cardiac Inflammation, Disease and Repair
  Michael Alexanian, PhD, Gladstone Institute, University of California, San Francisco

• Energy Metabolism in Cardiomyopathy and Heart Failure
  Rong Tian, MD, PhD, Mitochondria & Metabolism Center, University of Washington

• Immune-Mediated Cardiac Injury: From Checkpoints to Gene Therapies
  Javid Moslehi, MD, University of California, San Francisco
  
  

Session 2: Skeletal Muscle Biology

• Harnessing the Regenerative Potential of Human Pluripotent Stem Cell Derived Skeletal Muscle Stem Cells
  April Pyle, PhD, University of California, Los Angeles

• Modeling and Treating Disease by In Vivo Gene Editing with AAV-CRISPR
  Amy J. Wagers, PhD, Harvard University and Joslin Diabetes Center

• Genetic Modifiers of Myopathies
  Elizabeth McNally, MD, PhD, Northwestern University Feinberg School of Medicine
  
  

Session 3: Emerging Modalities to Treat Human Muscle Disease

• Emerging Genetic Medicines for Cardiomyopathies
  Laura Lombardi, PhD, Tenaya Therapeutics

• Unlocking the Broad Potential of RNA Medicines to Transform Human Health
  Erik Ingelsson, MD, PhD, Wave Life Sciences

• Weight Loss and Muscle Preservation
  Siddique Abbasi, MD, MSc, Amgen
  
  

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO^® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company is preparing to present the full results at an upcoming medical meeting and discuss them with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS^® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO^® is a trademark of Cytokinetics in the U.S., and a registered trademark in the European Union.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

What is the CLIMB 2026 muscle biology symposium hosted by Cytokinetics (NASDAQ: CYTK)?

CLIMB 2026 is a one-day, in-person research symposium focused on muscle biology. According to Cytokinetics, it brings together scientists and emerging professionals to share innovations in cardiac and skeletal muscle biology and emerging treatment modalities for muscle-related diseases and disorders.

When and where will Cytokinetics hold the CLIMB 2026 symposium?

Cytokinetics will hold CLIMB 2026 on May 29, 2026, from 8:00 AM to 5:00 PM PT. According to Cytokinetics, the event will take place at the Mission Bay Conference Center in San Francisco, California, as a one-day, in-person research meeting.

How can attendees register for the Cytokinetics CLIMB 2026 symposium and is there a fee?

Registration for CLIMB 2026 is free but capacity-limited. According to Cytokinetics, interested participants must register online at the symposium website by May 22, 2026, to secure a spot for the in-person event in San Francisco.

What topics will be covered at the Cytokinetics CLIMB 2026 muscle biology symposium?

CLIMB 2026 will cover cardiac biology, skeletal muscle biology and emerging modalities to treat muscle disease. According to Cytokinetics, sessions include energy metabolism, gene therapies, AAV-CRISPR gene editing, genetic modifiers of myopathies and emerging genetic and RNA medicines.

Who are some key speakers at Cytokinetics’ CLIMB 2026 symposium?

CLIMB 2026 features a keynote by James A. Spudich, PhD, co-founder of Cytokinetics. According to Cytokinetics, additional speakers include experts such as Michael Alexanian, Rong Tian, Javid Moslehi, April Pyle, Amy J. Wagers, Elizabeth McNally, Laura Lombardi and others.

What is the goal of the CLIMB 2026 symposium for Cytokinetics and the muscle biology community?

The goal is to foster collaboration and interdisciplinary dialogue in muscle biology research. According to Cytokinetics, CLIMB 2026 aims to advance understanding of muscle function and support emerging treatments for muscle-related diseases and disorders through talks, posters and networking.